ABSTRACT: The effect of natural emulsifiers (whey protein isolate, WPI; modified lecithin, ML; and gum arabic, GA) on the formulation, stability, and bioaccessibility of fucoxanthin-loaded oil-in-water (O/W) emulsions was determined in this study. The fine emulsions were prepared under high-pressure homogenization at 100 MPa for 4 passes, using 2 wt % WPI, ML, and GA, resulting in emulsions with the droplet sizes of 136, 140, and 897 nm, respectively. The chemical stability of fucoxanthin in the emulsions after long-term storage at ambient temperature decreased in the following order: WPI > GA > ML. The release of free fatty acids of fucoxanthin, studied by in vitro digestion, decreased in the following order: WPI > ML > GA > bulk oil. The bioaccessibility of fucoxanthin in emulsions stabilized by WPI, ML, and GA after in vitro digestion were 92.5 ± 6.8%, 44.6 ± 0.4, and 36.8 ± 2.5, respectively. These results indicate that natural emulsifier type and concentration used significantly affects the formulation, stability, lipid digestion, and fucoxanthin bioaccessibility, which may be ascribed to the different properties of each emulsifier. The bioaccessibility of fucoxanthin was improved by using emulsion-based delivery systems.
INTRODUCTION
With the constant pursuit of better life quality and healthier lifestyle, consumers are increasingly concerned about their health, and paying more attention to nutraceutical ingredients, such as vitamins and carotenoids. Fucoxanthin, a marine carotenoid found in brown seaweed, with a distinctive allenic bond in the 5,6-monoepoxide and hydroxyl groups, is an accessory pigment in the chloroplasts and is involved in photosynthesis. 1 Fucoxanthin is known to possess many beneficial properties, including antioxidant, 2, 3 anticancer, 4, 5 anti-inflammatory, 6 anti-obesity, and antidiabetic effects. 7, 8 A previous study investigated the effect of fucoxanthin supplementation, using ThinOgen, on body fat in overweight humans. 9 The results revealed that subjects in the treatment group (fucoxanthin 2−4 mg/day intake) showed a significant reduction in weight, compared to that by subjects in the placebo group. Moreover, another research illustrated that consumption of fucoxanthin-fortified milk leads to enhanced bioaccessibility of fucoxanthin in in vitro and in vivo models. 10 Therefore, fucoxanthin can be considered as a nutraceutical ingredient and can be utilized in the food industry and other fields to design new and improved nutraceuticals. However, as with other carotenoids, fucoxanthin is affected by light, oxygen, heat, and pH. 11, 12 Owing to its many limitations, such as its poor water-solubility (0.5 ppm), high melting point (166−168°C
), chemical variability, and low bioaccessibility, 13, 14 there are many challenges to its incorporation into nutraceutical products.
Food-grade emulsions are widely used in cosmetics, pharmaceuticals, foods, and beverages. 15 Various studies have indicated that emulsions could improve the stability and the bioavailability of nutraceutical ingredients when incorporated into dispersed phase droplets. O/W emulsion-based delivery systems are quite suited to encapsulate lipophilic bioactive ingredients due to the dispersion of small lipid droplets in the continuous phase. These droplets can efficiently pass through the skin and enhance the penetration of the components. 16, 17 Previous studies have demonstrated successful encapsulation of highly purified fucoxanthin into nanoemulsions, nanoparticles, and other spray-dried powders. 10,18−21 Most of them focused on the stability and bioaccessibility of fucoxanthin, which were affected by carrier oils (corn oil, medium chain triacylglycerol oil, orange flavor oil, and restructured lipids) and dispersions (whole milk and skimmed milk). Meanwhile, there is limited information about the comparison of various types of emulsifiers. For instance, fucoxanthin-loaded nanoemulsions were successfully prepared and characterized with Tween 80. Fucoxanthin-loaded nanoparticles of casein and chitosan showed improved bioavailability due to high absorption and entry into the blood. 18 There are no reports about using crude fucoxanthin extract and different naturally occurring emulsifiers for the formulation of fucoxanthin-loaded emulsions.
This study aimed to utilize natural emulsifiers instead of synthetic surfactants to formulate emulsions, which are sustainable and label friendly. Natural emulsifiers are mainly classified into protein-based emulsifiers, phospholipid-based emulsifiers, and polysaccharide-based emulsifiers. It is an established fact that emulsifiers are crucial to the formulation and stability of emulsion-based systems and that they protect emulsions against destabilizing processes. In this study, we utilized three natural emulsifiers: whey protein isolate (WPI), modified lecithin (ML) and gum arabic (GA) to formulate emulsions. We also evaluated the effects of the emulsifier type and concentration on the physicochemical stability of emulsions encapsulating fucoxanthin. WPI (mainly consisting of β-lactoglobulin and α-lactalbumin) is widely used as a foodgrade emulsifier in food and beverage products. 16 Hydrophilically modified phospholipid, which is hydrolyzed by soy lecithin, was used in this study. ML has a low molecular weight (about 650 g/mol), and because of its zwitterionic nature, it can stabilize emulsions by electrostatic repulsions during processing and storage. In addition, GA is generally utilized as an amphiphilic polysaccharide in the food industry (in juices and candies). It is a soluble dietary fiber, with specific properties due to a complex mixture of polysaccharides and glycoproteins. In this study, we evaluated the effects of the emulsifier type and concentration, apart from homogenization parameters, on the formulation and stabilization of fucoxanthin-loaded O/W emulsions. Subsequently, the characteristics of the emulsions, including the volume mean diameter, droplet size distribution, physicochemical stability, and fucoxanthin retention, were investigated. Moreover, we also investigated the effects of different emulsifiers on the in vitro digestion behavior and bioaccessibility of fucoxanthin by evaluating the amount of free fatty acids (FFAs) released and fucoxanthin concentration in the micellar phase. (Figure 1b) can be attributed to the fact that there was not sufficient emulsifier available to adsorb at oil/water interface during homogenization. 22 At high emulsifier concentrations, the d 4,3 values remained constant because the disruptive energy of the homogenizer was not enough for further size reduction. 23 Fine droplets with the minimum droplet diameters (d 4,3 ) of ≈128 nm (WPI), ≈137 nm (ML), and ≈611 nm (GA), respectively, were obtained at high emulsifier concentrations (4 wt %). The difference in droplet size was likely due to the contribution of the different emulsifiers to the interfacial behavior. ML dissolved in Milli-Q water had smaller interfacial tension than Milli-Q water, which was favorable for formulating small droplets. In contrast, the higher interfacial tension for WPI and GA can be ascribed to their largemolecular structures, which prevent close packing of the points of contact at the interface. 24 The coalescence of droplets occurred due to the splitting of droplets in a short period of time, in the homogenizer, which could not be fleetly stabilized by the large-molecule emulsifiers due to their low adsorption kinetics. 25 For WPI and GA, a smaller droplet size of emulsions formulated was observed. This could be explained based on the structural change in WPI during homogenization. There might be more hydrophobic groups exposed by the protein chain due to unfolding during adsorption. GA has a 21−28 nm gyration radius of globular configuration, and it is not as good a protein in reducing interfacial tension. 26 Therefore, under the same conditions, WPI may be faster and more efficient in covering the droplet surface than GA, thus resulting in the formulation of smaller droplets. However, the d 4,3 of GA-stabilized emulsions slightly increased from 760 to 904 nm. This phenomenon could be interpreted by the interdigitation of carbohydrates and protein denaturation in GA during the high-pressure process, which hindered the emulsifying capacity of GA. 25 Meanwhile, after 80 MPa and 3 passes, there was no distinct change in d 4, 3 . The d 4,3 of WPIor ML-stabilized emulsions decreased from 389 to 134 and 275 to 137 nm, respectively. Importantly, the chemical stability of fucoxanthin during the homogenization of emulsions, homogenized by different number of passes was also investigated. After the homogenization by using a rotor-stator homogenizer (pass 0, Figure 2b ), the chemical stability of fucoxanthin during homogenization fell to nearly 65−80% which meant around 20−35% of fucoxanthin degraded in this process. Therefore, the first step in the homogenization process has a crucial effect on the degradation of fucoxanthin. On the other hand, there was a gradual decrease in the chemical stability of fucoxanthin during homogenization with increasing number of passes during the high-pressure homogenization process. Although the changes were minimal, the impact of this aspect should not be ignored. The chemical stability of fucoxanthin during homogenization in WPI-, ML-, or GA-stabilized fresh O/W emulsions were 72.7, 65.6, and 56.0%, respectively. This phenomenon can be explained by the following three factors: (i) during high-speed homogenization, the coarse emulsions were exposed to the atmosphere, and oxygen might be entrapped in the emulsions. (ii) After preparing the coarse emulsions, the dispersed phase was separated from the continuous phase rapidly. Even if highspeed homogenization can provide strong shear force, it is still a failure to make the emulsifiers to fully adsorb on the surface of droplets and formulate a better droplet form. (iii) During the high-pressure homogenization, because of the high energy input, free radicals may have been formed as fucoxanthin is sensitive to thermal energy. 28 
Influence of Homogenization Pressures and

Storage Stability of Fucoxanthin in O/W
Emulsions. The stability of the emulsion is a critical factor to determine the shelf-life of foods and beverages. Storage stability of fucoxanthin in emulsions stabilized by different types of emulsifiers (WPI, ML, or GA) was investigated during storage at 25°C, up to 15 days. Because of the unsaturated structure, fucoxanthin is sensitive to heat, light, and oxidative degradation during processing and storage. Therefore, all samples were covered by aluminum foil and stored in the dark. stabilized by different emulsifiers (WPI, ML, or GA) during storage up to 15 days, at 25°C. During storage, emulsions showed excellent physical stability and there was no prominent broadening in d 4, 3 , when stabilized by WPI or ML. WPI can form physically strong layers, which could avoid the coalescence of droplets by steric hindrance on the interface between oil and water. 29 ML-stabilized emulsions contained tiny particles which could counter the gravitational force with Brownian motion. Furthermore, the droplets carry a negative charge, which might inhibit flocculation. 30 Meanwhile, visible creaming occurred on top of the emulsion stabilized by GA. GA is an emulsifier with a large molecular structure and a high interfacial tension, which might result in relatively large droplets leading to a higher buoyancy force.
2.5. Chemical Stability of Fucoxanthin during Storage. The chemical stability of fucoxanthin during storage was measured by using eq 2. As shown in Figure 4 , the chemical stability of fucoxanthin at day 0 was deemed as 100%, which decreased in all emulsions during storage. The chemical stability of fucoxanthin during storage of emulsions stabilized by ML or GA was lower than the detection limit at day 3 and day 10, respectively. After storage at 25°C for 15 days, the chemical stability of fucoxanthin during storage decreased from 100 to 59.5% in WPI-stabilized emulsions and 55.5% in the case of bulk oil. The main factors that cause the degradation of fucoxanthin during storage are emulsifier type, surface area of the droplets, and the formation of free radicals during the highpressure process. 31 According to a previous study, the degradation of the carotenoid may be due to a chemical reaction on the surface, at the interface of oil and water, which may be slower in rate due to the smaller surface area. 32 Although WPI-and ML-stabilized emulsions had larger surface area, the latter was easier to be oxidized and decomposed, owing to more contact between oil and water, resulting in fucoxanthin exposure to oxygen. ML is the small molecular emulsifier, whose molecular weight is around 650 g/mol. It can be closely contacted and adsorbed on the surface of oil drop with a thin layer. WPI contains cysteyl residues, thiol functional groups, and disulfide bonds, which might inhibit lipid oxidation by scavenging free radicals in emulsion systems. 33 Additionally, the layer of adsorbed WPI might be considered as a thicker physical barrier than ML at the interface of oil and water and prevent fucoxanthin degradation. 34 Therefore, WPI can alleviate the degradation of fucoxanthin because of its good antioxidant activity, as well as excellent emulsifying properties. Moreover, as a large molecular emulsifier, GA has higher interfacial tension. The droplet size was extremely larger in the GA-stabilized emulsion than in others. Although the surface area of droplets in GAstabilized emulsion was smaller, it is not as good as WPI to prevent the degradation of fucoxanthin.
2.6. Lipid Digestion. The particle size drastically increased after the exposure of emulsions to the small intestinal phase, regardless of the emulsifier type. The initial d 4,3 of emulsions stabilized by WPI, ML, or GA were around 136, 140, and 897 nm, which increased to 123, 108, and 121 μm, respectively, after digestion in the small intestinal phase ( Figure 5 ). Other studies also suggest that the droplets in emulsions aggregate and are resistant to in vitro digestion. 20, 35, 36 This phenomenon might be due to the lipid digestion products, such as colloidal particles, micelles, bilayers, liquid crystals, or vesicles, that are generated due to the hydrolysis of triacylglycerol molecules by lipases in the small intestinal phase. 35, 37 Notably, fatty acids, monoacylglycerols, and bile salts can produce mixed micelles in the small intestinal fluid. 38, 39 Moreover, the insoluble calcium-fatty acid soaps may be formulated during digestion. 20 On the other hand, the interfacial and core characteristics may change and lead to droplet aggregation.
In the in vitro digestion study, the emulsifier type has an important influence on the lipid digestion rate and level. 40 Lipid digestion was defined as FFA (%) values throughout digestion time (min) and monitored by a pH-stat method. Moreover, we compared the FFAs released in bulk oil and emulsions ( Figure 6 ). For the bulk oil, we observed very little amount of initial FFAs being released (about 5.9%), which can be explained by the fact that most of the bulk oil cannot be digested. The release of FFAs in emulsions was quite faster and higher than that in the bulk oil because the surface area of emulsion droplets was larger than the one of bulk oil. The larger surface area can promote the interaction of oil droplets with the lipase to enhance rapid FFAs release. 41 This also explained the reason why FFAs released in GA-stabilized emulsions were lower than those in emulsions formed by other emulsifiers. In previous studies, the FFAs in Tween 20-or Tween 80-stabilized emulsions were rapidly released. However, in our study, the FFAs release was slow during the digestion. The possible mechanism can be explained by the shielding effects of Ca 2+ , which were added in the digestion phase. Tween 20 and Tween 80 are nonionic emulsifiers, whereas WPI, ML, and GA are anionic emulsifiers. The anionic charged droplets can be aggregated or flocculated by the screening effect with the cationic Ca 2+ . Therefore, the rate of FFAs release observed in this study was much slower than previous studies.
2.7. Chemical Stability and Bioaccessibility of Fucoxanthin during Digestion. In our study, the chemical stability of fucoxanthin during the digestion in WPI-stabilized emulsion was almost 100%, whereas the one in ML-stabilized emulsions was only 53.6% (Table 1) . However, previous studies suggested no significant degradation of astaxanthin and β-carotene before and after digestion. 40, 42 This result has shown that the oxidation and degradation of the bioactive compound during digestion is highly dependent on the sample and emulsifier types. The chemical structure of fucoxanthin contains an allenic bond and conjugated carbonyl group, which provide the unique features of fucoxanthin. The chemical stability of astaxanthin and β-carotene was not as active as fucoxanthin. Moreover, WPI can act as an excellent emulsifier which alleviates the degradation of fucoxanthin. GA-stabilized emulsions had the large volume mean diameter and low FFAs released related to a large amount of oil floated on the digestive fluid, hence, it was difficult to detect the chemical stability of fucoxanthin after digestion. The same situation also occurred with the bulk oil.
The bioaccessibility of fucoxanthin was highly dependent on the type of emulsifier in the emulsions and was determined as the fraction of fucoxanthin merged with the mixed micelles in the micellar phase after digestion by using in vitro gastrointestinal digestion model. It is noticeable that the bioaccessibility of fucoxanthin was drastically improved by using emulsion-based delivery systems. The bioaccessibility of fucoxanthin in samples followed the order: WPI (92.5%) >ML (44.6%) > GA (36.8%) > bulk oil (ND), and correlated inversely with the order of the initial droplet size. Especially, the retention of fucoxanthin in the micelles of WPI-stabilized emulsions rose up to 68.4% which was drastically higher than those in the bulk oil. For emulsions, lipolysis was more rapid and sufficient with smaller initial droplets. Different studies also indicated that the initial droplet size of dispersion has a significant influence on the generation of micelles and the lower bioaccessibility of β-carotene with increasing initial droplet size. 42, 43 Although the high-pressure homogenization method can improve the bioaccessibility of fucoxanthin, its drawbacks should not be neglected. Table 1 shows that with further processing and digestion, the proportion of fucoxanthin retention decreased in every step. The reasons for the decrease of R f , such as high energy input, exposure to oxygen, and some other reasons, have been discussed above. Therefore, further studies are needed to solve the issues of reducing the degradation of fucoxanthin during processing and digestion.
In the present study, fucoxanthin could be successfully incorporated into O/W emulsions which were stabilized by WPI, ML, or GA. WPI and ML were able to formulate emulsions with smaller droplets. In contrast, GA-stabilized emulsions resulted in larger droplets. The long-term storage experiments showed that all emulsions exhibited good physical stability during storage for 15 days at 25°C. The R f in emulsions was highly dependent on the natural emulsifier type. Emulsions stabilized by WPI had the highest retention of fucoxanthin, probably due to the antioxidant properties of WPI. The in vitro digestion experiments indicated that emulsion-based delivery systems could notably enhance the bioaccessibility of fucoxanthin compared to that by bulk oil. Moreover, the type of natural emulsifier has a major effect on the lipid digestion and bioaccessibility. The release of FFAs and bioaccessibility of fucoxanthin in WPI-or ML-stabilized emulsions were higher than in the case of GA-stabilized emulsions. This was attributed to the lipid digestion and highly relied on the initial droplet size along with the larger surface area which could increase the lipolysis rate and FFAs release. The findings reported herein can provide valuable information about the bioaccessibility of hydrophobic bioactive compounds, such as fucoxanthin, which can be improved by using emulsion-based delivery systems formulated through highpressure homogenization method.
MATERIALS AND METHODS
3.1. Materials. Fucoxanthin extract samples (ThinOgen fucoxanthin oil 5%, fucoxanthin purity 5% by HPLC) were kindly donated by BGG-Japan Co., Ltd. (Tokyo, Japan). The source of fucoxanthin extract was Laminaria saccharina (L.) Lamouroux (Alga Kombu)-Syn: Laminaria japonicaor Undaria pinnatifida, Harvey (Wakame Algae). Medium-chain triacylglycerol (MCT-7) oil was purchased from Taiyo Kagaku Co., Ltd. (Mie, Japan). The triacylglycerol in MCT was reported to contain around 25% capric acid and 75% caprylic acid and polyglyceryl-5-laurate. WPI was procured from Nichiga, Japan Garlic Co., Ltd. (Gunma, Japan). ML (SLP whitelyso) was purchased from Tsuji Oil Mills Co., Ltd. (Tokyo, Japan). ML is a mixture of different phospholipids and contains lysophosphatidylcholine (18−30%), phosphatidylinositol (10−20%), phosphatidylcholine (2−8%), phosphatidylethanolamine (1−7%), and phosphatidic acid (0−5%). GA was purchased from Fujifilm Wako Pure Chem., Co. (Osaka, Japan). All other chemicals used were of analytical grade. Double distilled water (Milli-Q water) was used for the preparation of all solutions and emulsions.
3.2. Formulation of Fucoxanthin-Loaded O/W Emulsions. The dispersed phase was prepared by dispersing 4 wt % fucoxanthin extract in MCT oil and stirred at ambient temperature, overnight, to ensure that fucoxanthin completely dissolved. The samples were refined by passing through a poly(tetrafluoroethylene) (PTFE) syringe filter (0.45 μm) to eliminate undissolved particles. The continuous phases were prepared by dissolving 0.01−4 wt % emulsifiers (WPI, ML, or GA) in Milli-Q water and 0.02 wt % antimicrobial agent (sodium azide) was added. The fucoxanthin-loaded O/W emulsions were prepared by homogenizing the 10 wt % dispersed phase and the 90 wt % continuous phase at ambient temperature. Initially, coarse emulsions were homogenized by using a rotor−stator homogenizer (polytron, PT-3000 Kinematica-AG, Littace, Switzerland) at 10 000 rpm for 5 min and then passed through a high-pressure homogenizer (NanoVater, NV200, Yoshida Kikai, Japan) at a pressure range of 20−140 MPa for 0−10 passes to obtain the fine emulsions.
3.3. Characterization of Fucoxanthin-Loaded O/W Emulsions. A laser diffraction particle size analyzer (LS 13 320, Beckman Coulter, Brea, USA) was used to determine the droplet size and size distribution of the freshly prepared emulsions. This device works on the principle of laser diffraction to calculate the particle size distribution via the pattern of light scattered by the particles in the samples. where C t is the actual fucoxanthin concentration in the emulsions at a specific time during the storage, and C 0 is the actual fucoxanthin concentration in freshly prepared emulsions.
3.5. Measurement of Fucoxanthin Concentration in Emulsions. The concentrations of fucoxanthin in the emulsions and bulk oil were quantified using HPLC (JASCO International Co., Tokyo, Japan) equipped with an AS-2055 autosampler, a PU-980 pump system, and a UV-970 UV−vis spectrophotometric detector. A C-18 reversed phase column (as stationary phase, 4.6 × 250 mm; Shimpack VP-ODS, Japan) was used with the temperature set at 25°C. Fucoxanthin was extracted from emulsions and the dispersed phase prior to the HPLC analysis using a solvent extraction method: 200 μL of emulsion or a drop of dispersed phase (mass was analyzed) from the middle of the glass test tube was diluted to 10 mL with methanol in a volumetric flask to extract fucoxanthin and then ultrasonicated for 5 min. The samples were filtered using PTFE syringe filters (0.45 μm) and transferred to 2 mL HPLC vials; 20 μL of the filtered samples from HPLC vials were injected into the HPLC system. The mobile phase consisted of 10 wt % of Milli-Q water and 90 wt % of methanol. The mobile phase flow rate was set at 1 mL/ min. UV detection of fucoxanthin was monitored at 450 nm. Fucoxanthin concentration in samples was calculated using a standard curve (R 2 = 0.9995) and all of the analyses were repeated three times.
3.6. In Vitro Gastrointestinal Digestion. An in vitro gastrointestinal tract (GIT) model composed of gastric and intestinal phases was used in this study. There was a slight modification in the methodology, from previous studies, to simulate the biological fate of ingested samples. 20,44−46 The samples were diluted two times with Milli-Q water in order to have 5 wt % oil before passing through the GIT model.
3.7. Gastric Phase. The simulated gastric fluid (SGF) was prepared by dissolving 7 mL of HCl (35−37%) and 2 g of sodium chloride in 1 L of Milli-Q water, and then 3.2 g of pepsin was added. HCl (1 mol/L) was used to adjust the pH of SGF to 1.2. The diluted emulsions (15 g) were mixed with SGF (15 g), and the obtained mixture contained 2.5 wt % oil. NaOH (1 mol/L) was used to adjust the pH of the samples to 2.5. The samples were maintained under continuous agitation at 250 rpm for 2 h at 37°C.
3.8. Small Intestinal Phase. After the gastric digestion step, 30 g of the sample was adjusted to pH 7.0 immediately by using NaOH solution (1 mol/L). The simulated small intestinal fluid (SSIF) contained 1 mL of calcium chloride (110 mg/mL) dissolved in Milli-Q water and 4 mL of freshly prepared bile extract (46.87 mg/mL) dissolved in phosphate buffer (5 mM, pH 7.0). The SSIF was added into the samples and the pH was adjusted to 7.0. Subsequently, 2.5 mL of freshly prepared lipase suspension (24 mg/mL) dissolved in phosphate buffer (5 mM, pH 7.0) was incorporated into the mixture. The samples were transferred to clean beakers and incubated in a water bath with controlled temperature (37°C) and continuous agitation at 250 rpm. During 2 h of the small intestinal digestion process, NaOH solution (1 mol/L) was manually titrated into the mixture to maintain a pH of 7.0. The pH of the samples was monitored and NaOH solution was titrated to neutralize the FFAs released during the lipid digestion. 47 The volume of NaOH solution (L) was recorded throughout the digestion. The amount of FFAs released was calculated using eq 3, as follows
NaOH NaOH oil oil (3) where V NaOH (t) is the volume (L) of NaOH solution (1 mol/ L) titrated into the samples to neutralize the FFAs released at a certain digestion time (min), M NaOH is the molarity of NaOH solution used (mol), M oil is the molecular weight of the MCT oil (490 g/mol), and W oil is the initial mass (g) of the oil present in the reaction system. 3.9. Determination of Chemical Stability and Bioaccessibility of Fucoxanthin during Digestion. After the in vitro digestion, 10 mL of raw digesta was immediately collected and centrifuged (10 000g, MX-307 centrifuge, Tomy Digital Biology Co., Ltd., Tokyo, Japan) at an ambient temperature for 60 min. After centrifugation, samples were separated into three phases: a thin oil phase on top, a transparent micellar phase in the middle, and a sediment phase at the bottom. 40, 46 Fucoxanthin was assumed to be solubilized in the micellar phase. The extracted fucoxanthin from the raw digesta phase and micellar phase was collected and passed through a PTFE syringe filter (0.45 μm). Samples were added into an organic solvent (methanol) to extract fucoxanthin and, then, ultrasonicated for 5 min. The transparent phase was quantified using HPLC as described in Section 2.5. The chemical stability and bioaccessibility of fucoxanthin during digestion, and fucoxanthin retention (R f ) were calculated using eqs 4−6, respectively, as indicated below 
Step Initial (6) where fucoxanthin concentration in the raw digesta and micellar phase are C Digesta and C Micellar , respectively. C 0 is the actual fucoxanthin concentration in freshly prepared emulsions. C
Step is the actual fucoxanthin concentration in the samples at every step (homogenization, storage, digestion, and bioaccessibility), and C Initial is the fucoxanthin concentration, which is calculated from the initial amount added. 3.10. Statistical Analysis. Each experiment was performed at least twice. Statistical analysis was performed using analysis of variance at a confidence level of 95%. Statistix 8.1 software (Tallahassee, USA) was used to calculate the least significant difference based on the method described in a previous report. 
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